Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
OHB Pediatric And Research Alliance Enter Combination Agreement; To Be Renamed Oak Hill Bio And Listed On Nasdaq Under Ticker "OAKH"
RESEARCH ALLIANCE CORPORATION III ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
